Feed / ABBV

AbbVie Inc.

ABBV

Healthcare · 260.36 -1.1% today

Isolated · not yet confirmedMarket checked 1 Oct, 13:15 GMT-4

Market read

No connected market move is active around AbbVie Inc..

No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 26 directly disclosed connections are confirming.

Company-1.1% todayVolume comparison unavailable
Market groupNo active group readNo durable group available
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Demand is diverging across products, with Elahere growing while Juvederm declines on weaker demand and unfavorable pricing.
  • R&D expenses increased 20% to $2,472 million (16% of net revenues) for the three months ended March 31, 2026 due to increased funding to support all stages of the company’s pipeline assets.

Invalidation: The isolated read changes if ABBV's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Drug Manufacturers - General

No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 26 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Demand is diverging across products, with Elahere growing while Juvederm declines on weaker demand and unfavorable pricing.
  • R&D expenses increased 20% to $2,472 million (16% of net revenues) for the three months ended March 31, 2026 due to increased funding to support all stages of the company’s pipeline assets.

Company research

Understand the business, not just the ticker

As of Oct 1, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations615
Usable filing statements83
Verified relationships9
Evidence supporting the case
  • Latest annual revenue changed +8.6% year over year.
  • Operating margin changed +8.4 percentage points in the latest annual period.
  • Operating cash flow covered net income at 4.50x in the latest annual period.
  • Credit and interest rates has repeated favorable evidence across 3 filings.
  • Foreign exchange has repeated favorable evidence across 3 filings.
Evidence challenging the case
  • Demand and volume has repeated adverse evidence across 4 filings.
Questions before a position
  • P/E is 450% above the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 40% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 30, 2026

261.84
6m+20.4%12m+17.3%24m+36.9%
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$56.2B+22.7%$6.45+6.2%
2022-12-31$58.1B+3.3%$6.63+0.1%
2023-12-31$54.3B-6.4%$2.72-0.3%
2024-12-31$56.3B+3.7%$2.39+0.0%
2025-12-31$61.2B+8.6%$2.36+0.0%

What management says matters

Persistent and emerging business drivers

Demand and volumemixed · 4 filings
“Net revenues for Juvederm Collection decreased 3% for the three months ended March 31, 2026 primarily driven by decreased consumer demand, partially offset by favorable pricing due to customer loyalty program changes in the United States in the prior year and…”
10-Q · May 8, 2026 ↗
Legal and regulatory exposurepositive · 4 filings
“FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES Three months ended March 31, (in millions) 2026 2025 Cash flows provided by (used in): Operating activities $ 3,829 $ 1,635 Investing activities (574) (735) Financing activities 919 (1,258) Operating cash fl…”
10-Q · May 8, 2026 ↗
Credit and interest ratespositive · 3 filings
“Other Non-Operating Expenses (Income) Three months ended September 30, Nine months ended September 30, (in millions) 2025 2024 2025 2024 Interest expense $ 739 $ 720 $ 2,179 $ 2,106 Interest income (72) (129) (207) (556) Interest expense, net $ 667 $ 591 $ 1,…”
10-Q · Nov 4, 2025 ↗
Foreign exchangepositive · 3 filings
“Other Non-Operating Expenses (Income) Three months ended September 30, Nine months ended September 30, (in millions) 2025 2024 2025 2024 Interest expense $ 739 $ 720 $ 2,179 $ 2,106 Interest income (72) (129) (207) (556) Interest expense, net $ 667 $ 591 $ 1,…”
10-Q · Nov 4, 2025 ↗

Valuation discipline

Descriptive valuation snapshot

Price/sales 7.6× · EV/sales 8.6×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

260.36-1.1% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 1 Oct, 15:45 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ABBV. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for ABBV. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind ABBV

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

GMABGenmab A/SpartnerFeb 20, 2026 ▾

“Epkinly • In May 2025, Genmab A/S (Genmab) announced positive topline results from the Phase 3 trial evaluating Epkinly plus rituximab and lenalidomide versus rituximab and lenalidomide alone in adult patients with relapsed or refractory (R/R) follicular lymp…”

Depended on by

RGNX10.9% of RGNXcustomerMay 14, 2026 ▾

“As of December 31, 2025 and 2024, the Company had recorded $ 10.9 million and $ 11.3 million, respectively, due from AbbVie for net reimbursement of costs incurred for activities performed under AbbVie Collaboration Agreement, which was included in other curr…”

Filing peers

MRKINVAHALO

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 27 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ABBV is currently a Leader in the organic co-movement group Unknown Theme. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for ABBV; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.